Obermatt
See Similar Stocks →

Flags

Financial distress

Perrigo

NYQ:PRGO · IE00BGH1M568
PharmaceuticalsLarge

360

8
EV / EBIT61
Price / Owner Earnings67
Owner Earnings Yield1
Dividend Yield100
Price/Sales97
EV / Gross Profit62
Price/Book91
Return on Capital41
Cash Return on Capital18
Return on Equity16
EBIT Margin29
Gross Profitability41
Accruals92
Owner Earnings Margin16
Sales growth13
Profit Growth57
Long-Term EPS Growth23
Owner Earnings Growth1
Reinvestment32
Price momentum6
Debt load7
Refinancing98
Debt Payback1
Liquidity28
Analyst ratings20
Opinion Changes50
Price Target Upside55
Market mood11
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Perrigo doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryIreland
IndustryPharmaceuticals
SizeLarge
TypePublic Company
ExchangeNYSE
Founded2013
Employees4,096
Websiteperrigo.com
ISINIE00BGH1M568
Last UpdateApr 2, 2026
Index & Theme
NutraceuticalFast-Moving Consumer GoodsDermatologyLifestylePain ManagementRespiratoryWomen's HealthAllergyBiotechnologyManufacturingPharmaceutical

Description

Perrigo Company plc (‘Perrigo’), a leading pure-play self-care company, provides health and wellness solutions to meet the evolving needs of consumers. Perrigo provides access to trusted self-care solutions that can be used without the need to visit…

Analysis

Middle-of-the-road

Perrigo Company plc sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is weak; the safety picture is fragile. The company scores 4/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
34
2023202420252026

All-time high

98

May 2025

All-time low

31

Mar 2026

Average rank

57

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
97
73
80
85
Price/Earnings
76
84
65
54
Price/Book
91
89
90
88
Dividend Yield
100
90
92
74
Value (overall)
100
99
100
90

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Perrigo with its peers
Bayer
GER:BAYN
15
CountryGermany
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Haleon
LSE:HLN
31
CountryUK
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Recordati
MIL:REC
54
CountryItaly
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Faes Farma
MCE:FAE
44
CountrySpain
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Laboratorios Farmaceuticos Rovi
MCE:ROVI
46
CountrySpain
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Teva Pharmaceutical Industries
TLV:TEVA
23
CountryIsrael
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →